RxDoctor Payments Data

Caroline Chung, MD

Radiation Oncology · Houston, TXNPI 1336695279

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $6,577 of the $8,907 with a category attached, or 73.8%. 8 manufacturers reported payments, led by Novocure Inc. at 56.1% of the total. Reporting peaked in 2019 at $6,316 and has fallen 97.0% since, to $193 in 2024.

$8,907in general payments, 2019–2025

Across 18 payments — averaging $494.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure Inc.$5K
  • Elekta K.k.$2K
  • Raysearch Laboratories AB (publ)$931
  • Siemens Medical Solutions USA, Inc.$736
  • Elekta, Inc.$289
  • Elekta Instrument AB$279
  • plus $172 from 2 others
$3,647,511in research payments, 2019–2025

Across 11 payments — averaging $331,592 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Siemens Medical Solutions USA, Inc.$3.2M
  • Raysearch Laboratories AB (publ)$447K
  • Genentech, Inc.$220

What the payments were for

  • Speaking & faculty fees$6,57774%
  • Travel & lodging$2112%
  • Food & beverage$1,83921%
  • Entertainment$2793%

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novocure Inc.1$5,000
Elekta K.k.1$1,500
Raysearch Laboratories AB (publ)2$931
Siemens Medical Solutions USA, Inc.7$736
Elekta, Inc.4$289
Elekta Instrument AB1$279
Brainlab, Inc.1$95
Servier Pharmaceuticals LLC1$77

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,907 in reported general payments places this provider in the 85th percentile of 418 radiation oncology providers in Texas.

See all radiation oncology providers in Texas

Medicare billing

Part B allowed, 2024
$13,073
Medicare patients
11
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →